

& Preferred Lab Partners

Opioid Interpretation Aids

Opioid Cut-off and Approximate Urine Detection Times				
	LC-MS/MS	Approximate Urine		
Drug/Metabolite	Cut-off (ng/mL)	Drug Detection Window		
Buprenorphine	10	1-7 days		
Buprenorphine-glucuronide	50	1-14 days		
Norbuprenorphine	10	1-14 days		
Norbuprenorphine-glucuronide	10	1-14 days		
Codeine	50			
Codeine-glucuronide	50	— 1-3 days		
Heroin metabolite (6-MAM)	10	< 1 day		
Hydrocodone	50			
Norhydrocodone	50	— 1-3 days		
Dihydrocodeine	50			
Hydromorphone	50	1-3 days		
Hydromorphone-glucuronide	50			
Morphine	50			
Morphine-3-glucuronide	25	1-3 days		
Morphine-6-glucuronide	25			
Fentanyl	2	1-3 days		
Norfentanyl	2			
Meperidine	50	1-2 days		
Normeperidine	50	1-4 days		
Oxycodone	50			
Noroxycodone	50	1-3 days		
Oxymorphone	50			
Noroxymorphone	50			
Oxymorphone-glucuronide	50			
Tramadol	50	— 1-3 days		
O-desmethyltramadol	50			
Naloxone	25	1-3 days		
Methadone	50	— 1-14 days		
EDDP	50			

Opioid Metabolism



& Preferred Lab Partners




Image from Pesce, A., et al. Interpretation of Urine Drug Testing in Pain Patients. Pain Medicine 2012;13:868-885.

Opioid parent	Urine drug/metabolites	Known Impurities/Contaminants ^{1,2}
Codeine	Codeine; Codeine-glucuronide; Morphine;	Morphine
	hydrocodone;	Allowable limit 0.15%
	, ,	Typical 0.01 – 0.1%
Morphine	Morphine; Hydromorphone; Morphine-3-	Codeine
	glucuronide; Morphine-6-glucuronide	Allowable limit 0.5%
		Typical 0.01 – 0.05%
Hydrocodone	Hydrocodone; Norhydrocodone;	Codeine
	Hydromorphone; Hydromorphone-	Allowable limit 0.15%
	glucuronide; Dihydrocodeine	Typical 0 – 0.1%
Hydromorphone	Hydromorphone; Hydromorphone-	Morphine
	glucuronide	Allowable limit 0.15%
		Typical 0 – 0.025%
		Hydrocodone
		Allowable limit 0.1%
		Typical 0 – 0.025%
Oxycodone	Oxycodone; Noroxycodone; Oxymorphone;	Hydrocodone
	Oxymorphone-glucuronide	Allowable limit 1%
		Typical 0.02 – 0.12%
Oxymorphone	Oxymorphone; Oxymorphone-glucuronide	Hydromorphone
		Allowable limit 0.15%
		Typical 0.03 – 0.1%
		Oxycodone
		Allowable limit 0.5%
		Typical 0.05 – 0.4%
Fentanyl	Fentanyl; Norfentanyl	None
Methadone	Methadone; EDDP	None
Buprenorphine	Buprenorphine; Buprenorphine-	None
	glucuronide; Norbuprenorphine;	
	Norbuprenorphine-glucuronide	
Tramadol	Tramadol; O-desmethyltramadol	None
Meperidine	Normeperidine	None



& Preferred Lab Partners

	Heroin	6-MAM; Morphine	Acetylcodeine (which is further metabolized to codeine)	
1. Pesce, A., et al. Interpretation of Urine Drug Testing in Pain Patients. Pain Medicine 2012;13:868-885.				

2. Nagpal, G., et al. Interpretation of Urine Drug Screens. JAMA 2017;318(17):1704-5.

Opioid Notes

Opioids undergo phase I metabolism by the CYP pathway, phase II metabolism by conjugation, or both. Phase I metabolism of opioids primarily involves CYP3A4 and CYP2D6 enzymes. Drug-drug interactions may occur when opioids are used concurrently with inducers or inhibitors of CYP enzymatic pathways. Morphine, oxymorphone, and hydromorphone undergo phase II glucuronidation, and their glucuronide forms are directly detected by this assay.

Unlike immunoassays, the LC-MS/MS method can identify both parent compounds and their metabolites. Historically patient chronic opioid therapy (COT) non-adherence may have been presumed if both parent compound and metabolite were not present. However, more recently published evidence has demonstrated that in some cases only the metabolite may be present with no evidence of parent medication. In other cases, only high levels of the parent medication are present with little to no metabolite.

Approximately 7-10% of Caucasians lack an active CYP2D6 enzyme and are unable to metabolize codeine to morphine. Metabolism of codeine can also be impacted due to the influence of CYP2D6 inhibitors, including Paxil[®] or Wellbutrin[®].

Hydromorphone is a minor metabolite of morphine, and its concentration rarely exceeds 2% of urine morphine concentration in patients taking morphine³.

For patients prescribed Suboxone[®] a metabolite-to-parent drug ratio of about 4.52 is expected³.

For patients prescribed methadone a ratio of methadone to EDDP (inactive metabolite) of about 1:1 is expected in urine³, although absolute concentrations found in a given urine sample may be highly variable. Urinary excretion of methadone decreases with increasing urine pH.

The presence of 6-acetylmorphine (6-MAM) is conclusive evidence of prior heroin use. Because half-life for 6-MAM is short, it may be detected in urine only up to 8 hours after administration. Morphine or its metabolites may be the only compound(s) detected following heroin use. Illicit heroin frequently contains small amounts of acetylcodeine, which is further metabolized to codeine. The presence of both codeine and morphine in urine does not rule out the use of heroin.

3. Sobolesky, P., et al. Interpretation of Pain Management Testing Results Using Case Examples. JALM 2018;2(4):610-621.